The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...
CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, a synthetic biology company working on developing and providing any human cell type at scale, will present development and characterisation data on ...
bit.bio is a synthetic biology company that uses its cell identity coding platform to reprogram induced pluripotent stem cells to create any human cell type. With its cell identity coding platform, ...
Industrial meat’s livestock farming causes 11% of greenhouse emissions, according to the UN's Food and Agriculture Organization, but most people are not ready to cut meat from their diets. The ...
Prof. Roger Pedersen, Stanford University, and Dr. Thomas Moreau, bit.bio, will give an overview of the innovative history and recent developments in transcription factor-mediated cellular ...
BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...
The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results